TSHR and cyclic hematopoiesis: Inactivating heterozygous TSHR variants were present in 10.8% (4/37 cases) of our TDH cases with a heterogeneous clinical presentation: CH severity was inconstant, especially for the hot spot variant Arg450His leading to both subclinical (F6) and severe CH (F15).